Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone - PubMed (original) (raw)

Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone

F Keime-Guibert et al. J Neurol Neurosurg Psychiatry. 2000 Apr.

Abstract

Objectives: To evaluate the effect of a combination of immunoglobulins (IVIg), cyclophosphamide (CTX), and methylprednisolone (MP) on the clinical course of patients with paraneoplastic neurological syndrome (PNS) and antineuronal antibodies (Abs).

Methods: Seventeen patients with paraneoplastic encephalomyelitis/sensory neuropathy (PEM/SN) with anti-Hu Abs (n = 10) or cerebellar degeneration (PCD) with anti-Yo Abs (n = 7) received one to nine cycles (mean 3.5) of a combination of IVIg (0.5 g/kg/day from days 1 to 5), CTX (600 mg/m2 at day 1) and MP (1g/day from day 1 to 3). The Rankin scale (RS) was used to evaluate the response. A positive response was considered as either improvement or stabilisation in patients who were still ambulatory (RS< or =3) at the onset of treatment, whereas only improvement, and not stabilisation, was considered a therapeutic benefit in bedridden patients (RS> or =4).

Results: Tolerance was good and no patient experienced grade 3/4 toxicity (World Health Organisation). Sixteen patients were evaluable for response. Of the seven patients with RS> or =4, none improved. Of the nine patients with RS< or =3, none improved but three (two SN and one PCD) stabilised for 4, 35, and 16 months.

Conclusions: This study suggests that vigorous immunosuppressive treatment is not useful in severely disabled PNS patients with antineuronal Abs. In a minority of patients (mainly with SN) who are not severely disabled at the onset of treatment, a transient stabilisation is possible and deserves further evaluation.

PubMed Disclaimer

Cited by

Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors.
Farina A, Villagrán-García M, Ciano-Petersen NL, Vogrig A, Muñiz-Castrillo S, Taillandier L, Michaud M, Lefilliatre M, Wang A, Lepine Z, Picard G, Wucher V, Dhairi M, Fabien N, Goncalves D, Rogemond V, Joubert B, Honnorat J. Farina A, et al. Neurol Neuroimmunol Neuroinflamm. 2022 Nov 29;10(1):e200058. doi: 10.1212/NXI.0000000000200058. Print 2023 Jan. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 36446613 Free PMC article.
Intravenous immunoglobulins in paraneoplastic brainstem encephalitis with anti-Ri antibodies.
Fumal A, Jobe J, Pepin JL, Delvaux V, Senterre JM, Bonaventure S, de Noordhout AM. Fumal A, et al. J Neurol. 2006 Oct;253(10):1360-1. doi: 10.1007/s00415-006-0199-7. Epub 2006 Sep 27. J Neurol. 2006. PMID: 17006632 No abstract available.
Paraneoplastic Cerebellar Degeneration with Anti-CV2/CRMP5 Antibodies in Ovarian Cancer: Case Report and Review of the Literature.
Juárez-Vignon Whaley JJ, Carrera-Muiños A, Hernandez-Gutierrez KG, Rodriguez-Cid JR, Otero-Cerdeira ME, Garcia-Montes V. Juárez-Vignon Whaley JJ, et al. Case Rep Oncol. 2021 Dec 20;14(3):1799-1805. doi: 10.1159/000519969. eCollection 2021 Sep-Dec. Case Rep Oncol. 2021. PMID: 35111012 Free PMC article.
Recent Advances in the Treatment of Cerebellar Disorders.
Mitoma H, Manto M, Gandini J. Mitoma H, et al. Brain Sci. 2019 Dec 23;10(1):11. doi: 10.3390/brainsci10010011. Brain Sci. 2019. PMID: 31878024 Free PMC article. Review.
Paraneoplastic limbic encephalitis associated with mixed olfactory neuroblastoma and craniopharyngioma: A case report and literature review.
Nagafuji H, Yokoi H, Fujiwara M, Sato D, Saito K. Nagafuji H, et al. Medicine (Baltimore). 2018 Jun;97(24):e10932. doi: 10.1097/MD.0000000000010932. Medicine (Baltimore). 2018. PMID: 29901583 Free PMC article. Review.

References

1. Neurology. 1984 Apr;34(4):480-5 - PubMed
1. Muscle Nerve. 1997 Dec;20(12):1576-82 - PubMed
1. Arch Neurol. 1987 Jun;44(6):600-4 - PubMed
1. Neurology. 1990 Feb;40(2):209-12 - PubMed
1. Neurology. 1990 Jul;40(7):1085-91 - PubMed

Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone - PubMed (original) (raw)